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AAV8

:   adeno‐associated virus serotype 8

*Abcg*

:   ATP‐binding cassette group G

AFLD

:   alcoholic fatty liver disease

ALT

:   alanine aminotransferase

AST

:   aspartate aminotransferase

ApoC‐II

:   apolipoprotein C‐II

CASP3

:   caspase 3

CD36

:   cluster differentiation factor 36

CEH

:   cholesteryl ester hydrolase

CES1

:   carboxylesterase 1

*Cpt1/2*

:   carnitine palmitoyltransferase 1 and 2

CYP7A1

:   cholesterol 7α‐hydroxylase

EtOH

:   ethanol

FAO

:   fatty acid oxidation

FC

:   free cholesterol

FFA

:   free fatty acid

FLD

:   fatty liver disease

FPLC

:   fast protein liquid chromatography

FXR

:   farnesoid X receptor

GC‐MS

:   gas chromatography--mass spectrometry

HDL‐C

:   high‐density lipoprotein cholesterol

IL

:   interleukin

LDL‐C

:   low‐density lipoprotein cholesterol

LDLR

:   low‐density lipoprotein receptor

LPL

:   lipoprotein lipase

MDA

:   malondialdehyde

NAFLD

:   nonalcoholic fatty liver disease

PCR

:   polymerase chain reaction

*Pdk4*

:   pyruvate dehydrogenase kinase isozyme 4

PPARα

:   peroxisome proliferator‐activated receptor α

ROS

:   reactive oxygen species

*Smad2/3*

:   mothers against decapentaplegic homolog family members 2 and 3

SREBP‐2

:   sterol regulatory element‐binding protein 2

TC

:   total cholesterol

TG

:   triglyceride

TGH

:   triglyceride hydrolase

TNFα

:   tumor necrosis factor α

TUNEL

:   triglyceride terminal deoxynucleotidyl transferase--mediated deoxyuridine triphosphate nick‐end labeling

VLDL

:   very low density lipoprotein

Fatty liver disease (FLD), characterized by abnormal lipid accumulation within hepatocytes, can be classified into nonalcoholic fatty liver disease (NAFLD) and alcoholic fatty liver disease (AFLD). FLD ranges from simple steatosis to steatohepatitis, which may further progress to cirrhosis and hepatocellular carcinoma.[1](#hep41487-bib-0001){ref-type="ref"}, [2](#hep41487-bib-0002){ref-type="ref"} Despite extensive research, the pathophysiology of FLD is not well understood.

In addition, no Food and Drug Administration--approved therapies are available for treatment of FLD.

Carboxylesterase 1 (CES1) is a drug‐metabolizing enzyme that has the ability to hydrolyze amide or ester bonds.[3](#hep41487-bib-0003){ref-type="ref"} Mouse *Ces1* has eight genes that are expressed in a wide variety of cell types and tissues.[4](#hep41487-bib-0004){ref-type="ref"} Among the eight mouse *Ces1* genes, *Ces1d* and *Ces1g* are relatively well‐characterized, which share 78% and 74% homology in amino acids with human *CES1*, respectively. Mouse *Ces1g* has been shown to display triglyceride hydrolase (TGH) activity,[5](#hep41487-bib-0005){ref-type="ref"} and global or hepatocyte‐specific inactivation of mouse *Ces1g* causes fatty liver and a pro‐atherogenic lipid profile.[5](#hep41487-bib-0005){ref-type="ref"}, [6](#hep41487-bib-0006){ref-type="ref"} On the contrary, hepatic expression of *Ces1g* improves liver steatosis, dyslipidemia, and insulin signaling.[5](#hep41487-bib-0005){ref-type="ref"}, [7](#hep41487-bib-0007){ref-type="ref"}, [8](#hep41487-bib-0008){ref-type="ref"} Global inactivation of *Ces1g* is also shown to aggravate alcohol‐deficient or methionine/choline‐deficient diet‐induced liver inflammation and liver injury.[9](#hep41487-bib-0009){ref-type="ref"}

In contrast to *Ces1g*, global or liver‐specific *Ces1d^−/−^* mice show reduced hepatic triglyceride accumulation and improved dyslipidemia and insulin sensitivity.[10](#hep41487-bib-0010){ref-type="ref"}, [11](#hep41487-bib-0011){ref-type="ref"}, [12](#hep41487-bib-0012){ref-type="ref"}, [13](#hep41487-bib-0013){ref-type="ref"} Interestingly, global loss of *Ces1g* or *Ces1d* attenuates the development of atherosclerosis in low‐density lipoprotein receptor (*Ldlr^−/−^*) mice.[12](#hep41487-bib-0012){ref-type="ref"}, [14](#hep41487-bib-0014){ref-type="ref"} In mice with global *Ces1g* deficiency, intestinal cholesterol and fat absorption is inhibited, whereas macrophage cholesterol efflux is increased,[14](#hep41487-bib-0014){ref-type="ref"} which may account for the athero‐protective effect of global *Ces1g* deficiency. Given that *Ces1d* and *Ces1g* have differing functions in lipid metabolism and that the functions of other *Ces1* isoforms remain to be characterized, it is essential to investigate the role of human CES1 in lipid metabolism directly.

Human CES1 is abundantly expressed in liver and has been shown to have cholesteryl ester hydrolase (CEH) activities.[15](#hep41487-bib-0015){ref-type="ref"} Liver‐specific transgenic expression of human *CES1* attenuates atherosclerosis in *Ldlr^−/−^* mice by promoting high‐density lipoprotein--mediated reverse cholesterol transport.[16](#hep41487-bib-0016){ref-type="ref"} In addition, macrophage‐selective overexpression of human CES1 also reduces atherosclerosis in *Ldlr^−/−^* mice through increased cholesterol efflux.[17](#hep41487-bib-0017){ref-type="ref"} So far, the role of human CES1 in regulating FLD or dyslipidemia remains to be determined.

In this report, we show that adeno‐associated virus serotype 8 (AAV8)--mediated overexpression of human CES1 in hepatocytes protects against high‐fat/high‐cholesterol/high‐fructose diet--induced or alcohol‐induced steatohepatitis and hyperlipidemia. We also investigated the underlying mechanisms. Our data suggest that human CES1 in hepatocytes is protective against metabolic disorders.

Materials and Methods {#hep41487-sec-0002}
=====================

Mice and Diets {#hep41487-sec-0003}
--------------

Twelve‐week‐old male C57BL/6J mice were purchased from the Jackson Laboratory (Bar Harbor, ME). Mice were fed for 16 weeks a high‐fat/high‐cholesterol/high‐fructose diet (Western diet) containing 40% fat/0.2% cholesterol (AIN‐76A; TestDiet, St. Louis, MO) and 4.2% fructose (in drinking water). The Lieber‐DeCarli diet was purchased from Bio‐Serv (Flemington, NJ). All of the animals received human care according to the criteria outlined in the "Guide for the Care and Use of Laboratory Animals" prepared by the National Academy of Sciences and published by the National Institutes of Health. Mice were fasted for 5 to 6 hours before euthanasia during the light cycle. All of the animal studies were approved by the Institutional Animal Care and Use Committee at Northeast Ohio Medical University.

Adeno‐associated Viruses {#hep41487-sec-0004}
------------------------

The coding sequence of human CES1 was amplified by polymerase chain reaction (PCR) and cloned into an AAV vector under the control of a mouse albumin promoter (AAV8‐ALB‐hCES1). The creation of AAV8‐ALB‐Null has been described previously.[18](#hep41487-bib-0018){ref-type="ref"} AAV8‐ALB‐hCES1 or AAV8‐ALB‐Null (control) was produced by packaging AAV plasmids into serotype 8 and titrated by Vector Biolabs (Malvern, PA). Each mouse was intravenously injected with 3 × 10^11^ genomic copies of AAVs.

Chronic Plus Binge Alcohol Drinking {#hep41487-sec-0005}
-----------------------------------

The chronic plus binge alcohol drinking was performed as described previously.[9](#hep41487-bib-0009){ref-type="ref"}, [19](#hep41487-bib-0019){ref-type="ref"} Briefly, C57BL/6J mice were administered a Lieber‐DeCarli control liquid diet (Cat \# F1259SP; BioServ) for 5 days. On the sixth day, mice were fed a Lieber‐DeCarli liquid diet (Cat \# F1258SP; BioServ) containing 5% (vol/vol) ethanol or pair‐fed a Lieber‐DeCarli control liquid diet for 10 days. On the 16th day, mice were gavaged with a single dose of ethanol (3 g/kg body weight) or isocaloric maltose dextrin.

Hepatic Biochemical Analyses and Staining {#hep41487-sec-0006}
-----------------------------------------

Approximately 100 mg of liver tissues were homogenized in methanol, and lipids were extracted in chloroform/methanol (2:1 vol/vol) as described.[20](#hep41487-bib-0020){ref-type="ref"} Hepatic triglycerides (TGs) and total cholesterol (TC) were measured using Infinity reagents from Thermo Fisher Scientific (Waltham, MA). Hepatic total free fatty acids (FFAs) and free cholesterol (FC) were determined using kits from Wako Chemicals USA (Richmond, VA). Hepatic fatty acid composition was analyzed by gas chromatography--mass spectrometry (GC‐MS) as previously described.[21](#hep41487-bib-0021){ref-type="ref"} Hepatic hydroxyproline level was quantified using a kit from Cell Biolabs (STA675; San Diego, CA). Hepatic malondialdehyde (MDA) levels were measured using a thiobarbituric acid reactive substances assay kit (STA‐330; Cell BioLabs), and hepatic reactive oxygen species (ROS) were measured using an OxiSelect *in vitro* ROS/RNS Assay kit (STA‐347; Cell BioLabs) as described.[9](#hep41487-bib-0009){ref-type="ref"}, [18](#hep41487-bib-0018){ref-type="ref"} Liver apoptosis was detected using a kit from Abcam (Cat \# ab206386; Cambridge, United Kingdom). Hepatic neutral lipid accumulation, morphology, and fibrosis were determined by Oil Red O staining, hematoxylin and eosin staining, and picrosirius red staining, respectively, and images were acquired using an Olympus microscope.

Analysis of Plasma Lipids, Lipoproteins, and Biochemistry {#hep41487-sec-0007}
---------------------------------------------------------

Plasma levels of triglycerides, cholesterol, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured using Infinity reagents (Thermo Fisher Scientific). Plasma lipoprotein profile was analyzed by fast protein liquid chromatography (FPLC) as previously described.[22](#hep41487-bib-0022){ref-type="ref"} Plasma high‐density lipoprotein cholesterol (HDL‐C) and non‐HDL‐C levels were determined using a high‐density lipoprotein and low‐density lipoprotein/very low density lipoprotein (VLDL) quantification kit from BioVision Inc. (Cat \# K613; Milpitas, CA). Plasma tumor necrosis factor α (TNFα), interleukin (IL)‐6, and IL‐1β levels were quantified using enzyme‐linked immunosorbent assay kits from PeproTech (Rocky Hill, NJ).

Real‐Time PCR and Western Blot Assays {#hep41487-sec-0008}
-------------------------------------

Total RNA was isolated with TRIzol reagent (Thermo Fisher Scientific), and mRNA levels were quantified by quantitative real‐time PCR using Powerup SYBR Master mix (Thermo Fisher Scientific) on a 7500 Real Time PCR machine (Applied Biosystems, Foster City, CA). mRNA expression levels were normalized to 36B4. Western blot assays were performed using total cell lysates, microsomes, or nuclear extracts of the liver samples, as described previously.[21](#hep41487-bib-0021){ref-type="ref"} Antibodies against CES1 (cat \# ab45957) and Tubulin (cat \# ab4074) were purchased from Abcam. Antibodies against histone (Cat \# 9671) or caspase 3 (CASP3; total \[cat \# 9661\] or cleaved \[cat \# 9662\]) were purchased from Cell Signaling Technology (Danvers, MA). Antibodies against LDLR (cat \# NBP1‐06709), scavenger receptor group B type 1 (cat \# NB400‐101), sterol regulatory element‐binding protein 2 (SREBP‐2; cat \# NBP2‐20481), or calnexin (cat \# NB1001965) were purchased from Novus Biologicals (Littleton, CO). Cluster differentiation factor 36 (CD36) antibody (cat \# PA116813) was purchased from Thermo Fisher Scientific. Cholesterol 7α‐hydroxylase (CYP7A1) antibody was a gift from Dr. David Russell at the University of Texas Southwestern Medical School.

Bile Acid Extraction and Measurement {#hep41487-sec-0009}
------------------------------------

Bile acids in the liver, intestine, and gallbladder were extracted using ethanol. Bile acid levels in the liver, intestine, or gallbladder were determined using a bile acid kit (Diazyme, San Diego, CA). Total bile acids are the sum of bile acids in the liver, intestine, and gallbladder.

TGH Activity Assays {#hep41487-sec-0010}
-------------------

Hepatic microsome proteins were isolated, and TGH activity was measured using ^3^H‐triolein as substrates, as described previously.[21](#hep41487-bib-0021){ref-type="ref"}

Fatty Acid Oxidation {#hep41487-sec-0011}
--------------------

C57BL/6 mice were injected intravenously with AAV8‐ALB‐NULL or AAV8‐ALB‐hCES1 at a dose of 3 × 10^11^ genomic copies per mouse. After 72 hours, mouse primary hepatocytes were isolated and cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum in 12‐well dishes. Hepatocytes were then treated for 36 hours with media in the presence or absence of 100 mM ethanol. Fatty acid oxidation (FAO) was performed using ^3^H‐palmitate as substrates, as described previously.[5](#hep41487-bib-0005){ref-type="ref"}

Body Fat Content Measurement {#hep41487-sec-0012}
----------------------------

Body fat content was detected using Echo‐MRI (Echo‐MRI, LLC, Houston, TX) as described.[23](#hep41487-bib-0023){ref-type="ref"}

Statistical Analysis {#hep41487-sec-0013}
--------------------

Statistical significance was analyzed using unpaired Student *t* test and analysis of variance (*GraphPad Prism*, GraphPad Software, San Diego, CA). All data were expressed as mean ± SEM. Differences were considered statistically significant at *P* \< 0.05.

Results {#hep41487-sec-0014}
=======

Hepatocyte‐Specific Expression of Human CES1 Reduces Liver Steatosis by Promoting FAO in Western Diet--Fed Mice {#hep41487-sec-0015}
---------------------------------------------------------------------------------------------------------------

Given that multiple *Ces1* genes exist in mice and they do not appear to function similarly, we reasoned that it was critical to investigate human CES1 functions directly. We therefore generated an AAV that expressed human CES1 under the control of a mouse albumin promoter (AAV8‐ALB‐hCES1). AAV8‐ALB‐hCES1 or AAV8‐ALB‐Null was injected intravenously into C57BL/6 mice, which were then fed a Western diet for 16 weeks. Overexpression of hCES1 in hepatocytes had no effect on body weight (Supporting Fig. [S1](#hep41487-sup-0001){ref-type="supplementary-material"}A), but reduced body fat content (Supporting Fig. [S1](#hep41487-sup-0001){ref-type="supplementary-material"}B) and hepatic levels of TC, FC (Fig. [1](#hep41487-fig-0001){ref-type="fig"}A), TGs (Fig. [1](#hep41487-fig-0001){ref-type="fig"}B), and FFAs (Fig. [1](#hep41487-fig-0001){ref-type="fig"}C). Analysis of hepatic fatty acid composition using GC‐MS showed that human CES1 overexpression reduced C16:1, C18:0, and C18:1 fatty acids by 48%, 38% and 44%, respectively, in Western diet--fed mice (Fig. [1](#hep41487-fig-0001){ref-type="fig"}D). Histological staining studies showed that human CES1 overexpression reduced neutral lipid accumulation and improved liver histology (Fig. [1](#hep41487-fig-0001){ref-type="fig"}E).

![Hepatocyte‐specific expression of human CES1 prevents Western diet--induced hepatosteatosis by promoting lipolysis and FAO. C57BL/6 mice were injected intravenously with AAV8‐ALB‐Null or AAV8‐ALB‐hCES1 at a dose of 3 × 10^11^ genomic copies/mouse and fed a Western diet for 16 weeks (n = 8). (A) Hepatic cholesterol levels. (B) Hepatic TG levels. (C) Hepatic FFA levels. (D) Hepatic fatty acid composition analyzed by GC‐MS (n = 6‐8). (E) Representative images of liver sections stained with Oil Red O (top panel) or hematoxylin and eosin (bottom panel). (F) Liver microsome proteins were isolated and TGH activity was measured using ^3^H‐triolein as substrates. (G) Hepatic mRNA levels were quantified by quantitative real‐time PCR. (H) Mouse primary hepatocytes were isolated from C57BL/6 mice injected with AAV8‐ALB‐Null or AAV8‐ALB‐hCES1. FAO was determined using ^3^H‐palmitic acid as substrates (n = 5). *\*P* \< 0.05*, \*\*P* \< 0.01. Abbreviations: CE, cholesteryl ester; H&E, hematoxylin and eosin; ORO, Oil Red O.](HEP4-4-527-g001){#hep41487-fig-0001}

Consistent with a reduced hepatic TG levels, overexpression of human CES1 increased hepatic TGH activity by 166% (Fig. [1](#hep41487-fig-0001){ref-type="fig"}F). Newly released FFAs from lipolysis are known to serve as ligands for peroxisome proliferator‐activated receptor α (PPARα) to activate FAO.[5](#hep41487-bib-0005){ref-type="ref"}, [21](#hep41487-bib-0021){ref-type="ref"}, [24](#hep41487-bib-0024){ref-type="ref"} Consistent with these findings, overexpression of human CES1 increased hepatic mRNA levels of *Pparα* and its target genes *Cpt1* (carnitine palmitoyltransferase 1), *Cpt2* and *Pdk4* (pyruvate dehydrogenase kinase isozyme 4) (Fig. [1](#hep41487-fig-0001){ref-type="fig"}G), and increased FAO (Fig. [1](#hep41487-fig-0001){ref-type="fig"}H). The increased FAO may account for the reduced hepatic FFA levels (Fig. [1](#hep41487-fig-0001){ref-type="fig"}C). There was no change in hepatic levels of *Ces1d*, *Ces1g* or *Hnf4α* (Supporting Fig. [S1](#hep41487-sup-0001){ref-type="supplementary-material"}C), or genes involved in *de novo* lipogenesis (*Srebp1c*, *Cebpα*, *Acc*, and *Fasn*) or VLDL secretion (*Apob* and *Mttp*) (Supporting Fig. [S1](#hep41487-sup-0001){ref-type="supplementary-material"}D,E).

We have previously shown that fasting represses CES1 protein expression in the liver, likely due to reduced glucose availability.[8](#hep41487-bib-0008){ref-type="ref"} Consistent with this finding, fasting repressed the mRNA levels of *Ces1d* and *Ces1g* (Supporting Fig. [S2](#hep41487-sup-0001){ref-type="supplementary-material"}). Thus, although CES1 has TGH activity, hepatic CES1 likely promotes lipolysis during the fed state, as glucose is shown to induce CES1 expression.[8](#hep41487-bib-0008){ref-type="ref"} In addition, we could not fully rule out the possibility that CES1 also regulates *de novo* lipogenesis. Taken together, the data of Fig. [1](#hep41487-fig-0001){ref-type="fig"} demonstrate that human CES1 prevents Western diet--induced hepatosteatosis, likely by inducing lipolysis and FAO.

Hepatocyte‐Specific Expression of Human CES1 Ameliorates Western Diet--Induced Liver Inflammation, Apoptosis, and Fibrosis {#hep41487-sec-0016}
--------------------------------------------------------------------------------------------------------------------------

Excessive FFAs or FC can cause endoplasmic reticulum stress, mitochondrial dysfunction, apoptosis and inflammation,[25](#hep41487-bib-0025){ref-type="ref"}, [26](#hep41487-bib-0026){ref-type="ref"}, [27](#hep41487-bib-0027){ref-type="ref"} which play a key role in the progression of FLD from simple steatosis to steatohepatitis. The data of Fig. [1](#hep41487-fig-0001){ref-type="fig"} and Table [1](#hep41487-tbl-0001){ref-type="table"} indicate that human CES1 overexpression reduces hepatic FFA and FC levels, leading us to investigate whether human CES1 regulated apoptosis, inflammation, and liver injury. Hepatocyte‐specific overexpression of human CES1 reduced plasma ALT (Fig. [2](#hep41487-fig-0002){ref-type="fig"}A) and AST levels (Fig. [2](#hep41487-fig-0002){ref-type="fig"}B), and inhibited hepatic mRNA levels of inflammatory genes (*Tnfα*, *Il‐6*, *Il‐1β*, and *Mcp1* \[monocyte chemoattractant protein 1\]) (Fig. [2](#hep41487-fig-0002){ref-type="fig"}C) and fibrogenic genes (*Tgfβ* \[transforming growth factor β\], *α‐Sma*\[α smooth muscle actin\], *Timp1* \[tissue inhibitor of metalloproteinase 1\], *Col1a1* \[alpha‐1 type I collagen\], and *Col1a2* \[alpha‐2 type I collagen\]) (Fig. [2](#hep41487-fig-0002){ref-type="fig"}D).

###### 

Hepatic Fatty Acid Composition in Mice Fed an Alcohol Diet (μg/mg)

  Fatty Acids   Control Diet   Control Diet                                                                                    EtOH Diet                                                                                        EtOH Diet
  ------------- -------------- ----------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------ ---------------------------------------------------------
  C14:0         0.128 ± 0.02   0.106 ± 0.017                                                                                   0.308 ± 0.09[‡](#hep41487-note-0006){ref-type="fn"}                                              0.121 ± 0.02[§](#hep41487-note-0007){ref-type="fn"}
  C16:0         21.93 ± 3.36   37.49 ± 10.17                                                                                   48.38 ± 4.98[‡](#hep41487-note-0006){ref-type="fn"}                                              34.26 ± 2.73[§](#hep41487-note-0007){ref-type="fn"}
  C16:1         0.338 ± 0.05   0.366 ± 0.06                                                                                    0.768 ± 0.205                                                                                    0.178 ± 0.037[\|\|](#hep41487-note-0008){ref-type="fn"}
  C18:0         7.68 ± 0.31    6.2 ± 0.35[\*](#hep41487-note-0004){ref-type="fn"}, [†](#hep41487-note-0005){ref-type="fn"}     12.85 ± 1.13[\*](#hep41487-note-0004){ref-type="fn"}, [†](#hep41487-note-0005){ref-type="fn"}    8.41 ± 0.38[\|\|](#hep41487-note-0008){ref-type="fn"}
  C18:1         25.27 ± 3.63   27.36 ± 3.22                                                                                    61.71 ± 10.41[\*](#hep41487-note-0004){ref-type="fn"}, [†](#hep41487-note-0005){ref-type="fn"}   42.77 ± 0.65
  C18:2         11.64 ± 1.85   10.7 ± 1.26                                                                                     43.36 ± 5.85[‡](#hep41487-note-0006){ref-type="fn"}                                              27.31 ± 1.78[§](#hep41487-note-0007){ref-type="fn"}
  C20:4         0.53 ± 0.15    0.146 ± 0.04[\*](#hep41487-note-0004){ref-type="fn"}, [†](#hep41487-note-0005){ref-type="fn"}   0.225 ± 0.05[\*](#hep41487-note-0004){ref-type="fn"}, [†](#hep41487-note-0005){ref-type="fn"}    0.023 ± 0.007[\|\|](#hep41487-note-0008){ref-type="fn"}
  C22:6         7.99 ± 2.26    2.57 ± 0.51[\*](#hep41487-note-0004){ref-type="fn"}, [†](#hep41487-note-0005){ref-type="fn"}    3.34 ± 0.776[\*](#hep41487-note-0004){ref-type="fn"}, [†](#hep41487-note-0005){ref-type="fn"}    0.912 ± 0.05[§](#hep41487-note-0007){ref-type="fn"}

C57BL/6 mice were injected with AAV8‐ALB‐Null or AAV8‐ALB‐hCES1 and fed a control diet or EtOH diet. Hepatic fatty acid composition was analyzed by GC‐MS.

*P* \< 0.05 versus control diet--fed AAV‐Null group.

*P* \< 0.05.

*P* \< 0.01 versus control diet--fed AAV‐Null group.

*P* \< 0.05.

*P* \< 0.01 versus EtOH diet--fed AAV‐Null group.
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![Hepatocyte‐specific expression of human CES1 protects against Western diet--induced liver inflammation, apoptosis, and fibrosis in mice. C57BL/6 mice were injected intravenously with AAV8‐ALB‐Null or AAV8‐ALB‐hCES1 and fed a Western diet for 16 weeks (n = 8 per group). (A) Plasma ALT levels. (B) Plasma AST levels. Hepatic mRNA levels involved in inflammation (C) or fibrogenesis (D) were quantified by quantitative real‐time PCR. Hepatic proteins involved in apoptosis were detected by immunoblots (E) and quantified (F). (G) Apoptotic cells and fibrosis in the liver were stained by TUNEL assays (upper panel) and picrosirius red staining (bottom panel), respectively. (H) Quantification of apoptotic cells (percentage of total cells counted). (I) Hepatic hydroxyproline levels. (J) Hepatic 2′,7′‐dichlorodihydrofluorescein (ROS) levels. (K) Hepatic MDA levels. *\*P* \< 0.05*, \*\*P* \< 0.01. Abbreviations: DCF, 2′,7′‐dichlorodihydrofluorescein; P‐Smad, phosphorylated Smad2/3; T‐Smad, total Smad 2/3.](HEP4-4-527-g002){#hep41487-fig-0002}

Smad2 and Smad3 (mothers against decapentaplegic homolog 2/3 \[Smad2/3\]) are closely related downstream effectors in TGFβ‐induced apoptosis.[28](#hep41487-bib-0028){ref-type="ref"}, [29](#hep41487-bib-0029){ref-type="ref"} Consistent with the inhibition of *Tgfβ* expression (Fig. [2](#hep41487-fig-0002){ref-type="fig"}D), phosphorylated Smad2/3 levels as well as CASP3 levels were significantly reduced by human CES1 overexpression (Fig. [2](#hep41487-fig-0002){ref-type="fig"}E,F). TUNEL (terminal deoxynucleotidyl transferase--mediated deoxyuridine triphosphate nick‐end labeling) studies showed that human CES1 overexpression significantly suppressed apoptosis (Fig. [2](#hep41487-fig-0002){ref-type="fig"}G,H). Overexpression of human CES1 also reduced fibrosis (Fig. [2](#hep41487-fig-0002){ref-type="fig"}G), hydroxyproline levels (Fig. [2](#hep41487-fig-0002){ref-type="fig"}I), reactive oxygen species (ROS) (Fig. [2](#hep41487-fig-0002){ref-type="fig"}J), and MDA levels (Fig. [2](#hep41487-fig-0002){ref-type="fig"}K) in the liver. These data demonstrate that hepatocyte‐specific expression of human CES1 attenuates Western diet--induced steatohepatitis by inhibiting ROS production, lipid peroxidation, apoptosis, and inflammation.

Hepatocyte‐Specific Expression of Human CES1 Improves Hyperlipidemia in Western Diet--Fed Mice {#hep41487-sec-0017}
----------------------------------------------------------------------------------------------

In addition to attenuating steatohepatitis, hepatocyte‐specific overexpression of human CES1 also reduced plasma levels of non‐HDL‐C (Fig. [3](#hep41487-fig-0003){ref-type="fig"}A), TG (Fig. [3](#hep41487-fig-0003){ref-type="fig"}B), and FFAs (Fig. [3](#hep41487-fig-0003){ref-type="fig"}C). Analysis of plasma lipoprotein profiles by FPLC showed that human CES1 reduced plasma low‐density lipoprotein cholesterol (LDL‐C) levels (Fig. [3](#hep41487-fig-0003){ref-type="fig"}D). In the liver, overexpression of human CES1 significantly induced the mRNA levels of *Srebp2*, *Ldlr*, *Cyp7a1*, ATP‐binding cassette group G type 5 (*Abcg5*), *Abcg8*, apolipoprotein C‐II (*Apoc2*), and lipoprotein lipase (*Lpl*), but repressed *Cd36* mRNA levels (Fig. [3](#hep41487-fig-0003){ref-type="fig"}E). In addition, overexpression of human CES1 increased hepatic protein levels of LDLR, CYP7A1, and mature SREBP2 by 2.7, 2.2 and 2.9 fold, respectively, but reduced hepatic CD36 protein levels by 58% (Fig. [3](#hep41487-fig-0003){ref-type="fig"}F,G). Consistent with the induction of hepatic CYP7A1 expression, overexpression of human CES1 significantly increased bile acid levels in the intestine, liver, and gallbladder (Fig. [3](#hep41487-fig-0003){ref-type="fig"}H). The increased *Abcg5* and *Abcg8* expression may account for the reduced hepatic FC levels, which may subsequently promote the induction of SREBP2 and LDLR expression and a decrease in plasma LDL‐C levels. The induction in hepatic *Apoc2* and *Lpl* may account for the reduced plasma TG levels.

![Hepatocyte‐specific expression of human CES1 ameliorates Western diet--induced hyperlipidemia by inducing LDLR, ApoC‐II, and LPL. C57BL/6 mice were injected intravenously with AAV8‐ALB‐Null or AAV8‐ALB‐hCES1 and fed a Western diet for 16 weeks (n = 8 per group). Plasma levels of cholesterol (A), TG (B), and FFA were measured. (D) Plasma cholesterol lipoprotein profile was analyzed by FPLC. Hepatic mRNA levels were quantified by quantitative real‐time PCR (E). (F,G) Hepatic protein levels were determined by Western blotting. (H) Bile acid levels in the small intestine, gallbladder, or liver were measured, and total bile acid levels were determined. *\*P* \< 0.05*, \*\*P* \< 0.01. Abbreviations: GB, gallbladder; SI, small intestine.](HEP4-4-527-g003){#hep41487-fig-0003}

Hepatocyte‐Specific Expression of Human CES1 Increases Lipolysis and FAO and Attenuates Alcohol‐Induced Hepatosteatosis {#hep41487-sec-0018}
-----------------------------------------------------------------------------------------------------------------------

Although NAFLD and AFLD share the similar pathogenic spectrum (simple steatosis and steatohepatitis), their pathogenic causes are completely different. To investigate whether human CES1 also had a similar effect on AFLD, we fed C57BL/6 mice with a Lieber‐Decarli diet containing 5% ethanol or pair‐fed a control diet following a National Institute on Alcohol Abuse and Alcoholism protocol.[19](#hep41487-bib-0019){ref-type="ref"} The chronic plus binge ethanol feeding did not affect mouse body weight (Supporting Fig. [S3](#hep41487-sup-0001){ref-type="supplementary-material"}A) or body fat content (Supporting Fig. [S3](#hep41487-sup-0001){ref-type="supplementary-material"}B). Ethanol feeding significantly increased plasma levels of ALT (Fig. [4](#hep41487-fig-0004){ref-type="fig"}A) and AST (Fig. [4](#hep41487-fig-0004){ref-type="fig"}B) as well as hepatic levels of TG (Fig. [4](#hep41487-fig-0004){ref-type="fig"}C) and FFA (Fig. [4](#hep41487-fig-0004){ref-type="fig"}D). These increases were significantly attenuated by hepatocyte‐specific overexpression of human CES1 (Fig. [4](#hep41487-fig-0004){ref-type="fig"}A‐D). Oil red O staining showed that human CES1 reduced ethanol‐induced neutral lipid accumulation (Fig. [4](#hep41487-fig-0004){ref-type="fig"}E). In contrast, overexpression of human CES1 had no effect on ethanol‐induced changes in genes involved in *de novo* lipogenesis (*Srebp1c*, *Acc*, and *Fasn*) or VLDL secretion (*Apob* and *Mttp*) (Supporting Fig. [S3](#hep41487-sup-0001){ref-type="supplementary-material"}C‐G).

![Hepatocyte‐specific expression of human CES1 protects against alcohol‐induced liver steatosis. C57BL/6 mice were injected intravenously with AAV8‐ALB‐Null or AAV8‐ALB‐hCES1 (n = 16). After 2 weeks, the mice were fed a Lieber‐DeCarli control liquid diet for 5 days, followed by a Lieber‐DeCarli ethanol diet or pair‐fed a control diet for 10 days (n = 8). On the 16th day, a single dose of ethanol (3 g/kg) or isocaloric maltose dextrin was administered. Plasma levels of ALT (A) and AST (B) as well as hepatic levels of TG (C) and FFA (D) were determined. (E) Hepatic neutral lipids were stained by Oil Red O. (F) Hepatic TGH activity was analyzed. Hepatic mRNA levels of *Pparα* (G), *Cpt1* (H), *Cpt2* (I), and *Pdk4* (J) were quantified by quantitative real‐time PCR. (K) C57BL/6 mice were injected intravenously with AAV8‐ALB‐null or AAV8‐ALB‐hCES1. After 72 hours, mouse primary hepatocytes were isolated and treated for 36 hours with 100 mM ethanol or control media. FAO was determined using ^3^H‐palmitic acid as substrates (n = 4‐5). *\*P* \< 0.05*, \*\*P* \< 0.01. Abbreviation: EtOH, ethanol.](HEP4-4-527-g004){#hep41487-fig-0004}

Ethanol feeding repressed hepatic TGH activity (Fig. [4](#hep41487-fig-0004){ref-type="fig"}F) and hepatic genes involved in FAO, including *Pparα* (Fig. [4](#hep41487-fig-0004){ref-type="fig"}G), *Cpt1* (Fig. [4](#hep41487-fig-0004){ref-type="fig"}H), *Cpt2* (Fig. [4](#hep41487-fig-0004){ref-type="fig"}I) and *Pdk4* (Fig. [4](#hep41487-fig-0004){ref-type="fig"}J), which were all normalized by overexpression of human CES1 in hepatocytes (Fig. [4](#hep41487-fig-0004){ref-type="fig"}F‐J). In line with these findings, ethanol inhibited FAO in hepatocytes, which was normalized by overexpression of human CES1 (Fig. [4](#hep41487-fig-0004){ref-type="fig"}K). Thus, human CES1 attenuates alcohol‐induced hepatosteatosis likely by enhancing lipolysis and FAO.

In addition, we also analyzed hepatic fatty acid composition by GC‐MS. Alcohol treatment markedly increased C14:0, C16:0, C18:0, C18:1, and C18:2 fatty acid levels by 167%‐372%, and interestingly decreased C20:4 and C22:6 fatty acid levels, but did not change C16:1 fatty acid levels (Table [1](#hep41487-tbl-0001){ref-type="table"}). Overexpression of human CES1 in hepatocytes significantly attenuated alcohol‐induced increases in C14:0, C16:0, C16:1, C18:0, and C18:2 fatty acid levels, and reduced C20:4 and C22:6 fatty acid levels (Table [1](#hep41487-tbl-0001){ref-type="table"}). These data are consistent with a role of human CES1 in promoting FAO. Together, our data indicate that human CES1 attenuates alcohol‐induced hepatosteatosis likely by enhancing lipolysis and FAO.

Hepatocyte‐Specific Expression of Human CES1 Ameliorates Alcohol‐Induced Hyperlipidemia {#hep41487-sec-0019}
---------------------------------------------------------------------------------------

In addition to improving alcohol‐induced hepatosteatosis, human CES1 expression also reduced ethanol‐induced increases in plasma non‐HDL‐C levels (Fig. [5](#hep41487-fig-0005){ref-type="fig"}A). There was no change in plasma HDL‐C levels (Fig. [5](#hep41487-fig-0005){ref-type="fig"}B). In addition, human CES1 normalized ethanol‐induced increases in plasma TG (Fig. [5](#hep41487-fig-0005){ref-type="fig"}C) and FFA (Fig. [5](#hep41487-fig-0005){ref-type="fig"}D) levels. Consistent with these findings, overexpression of human CES1 normalized or increased hepatic expression of *Ldlr* (Fig. [5](#hep41487-fig-0005){ref-type="fig"}E), *Cyp7a1* (Fig. [5](#hep41487-fig-0005){ref-type="fig"}F), *Srebp2* (Fig. [5](#hep41487-fig-0005){ref-type="fig"}G), *Abcg5* (Fig. [5](#hep41487-fig-0005){ref-type="fig"}H), or *Abcg8* (Fig. [5](#hep41487-fig-0005){ref-type="fig"}I) in alcohol‐fed mice. Alcohol increased *Cd36* mRNA levels, which were completely normalized by human CES1 (Fig. [5](#hep41487-fig-0005){ref-type="fig"}J). In addition, human CES1 increased *Apoc2* (Fig. [5](#hep41487-fig-0005){ref-type="fig"}K) and *Lpl* (Fig. [5](#hep41487-fig-0005){ref-type="fig"}L) expression in alcohol‐fed mice. Our western blot assays further confirmed the mRNA expression data shown for *Ldlr*, *Cyp7a1*, and *Srebp2* (Fig. [5](#hep41487-fig-0005){ref-type="fig"}M).

![Human CES1 prevents alcohol‐induced hyperlipidemia. C57BL/6 mice were fed a control diet or alcohol as described in Fig. [4](#hep41487-fig-0004){ref-type="fig"} (n = 8 per group). Plasma levels of non‐HDL‐C (A), HDL‐C (B), TG (C), and FFA (D) were determined. Hepatic mRNA levels of *Ldlr* (E), *Cyp7a1* (F), *Srebp2* (G), *Abcg5* (H), *Abcg8* (I), *Cd36* (J), *Apoc2* (K), and *Lpl* (L) were quantified by quantitative real‐time PCR. (M) Hepatic proteins were analyzed by western blotting. *\*P* \< 0.05*, \*\*P* \< 0.01.](HEP4-4-527-g005){#hep41487-fig-0005}

Hepatocyte‐Specific Expression of Human CES1 Inhibits Inflammation in Alcohol‐Fed Mice {#hep41487-sec-0020}
--------------------------------------------------------------------------------------

Inflammation plays an important role in the pathogenesis of alcoholic liver disease. Alcohol feeding significantly increased hepatic mRNA levels of inflammatory genes including *Tnfα* (Fig. [6](#hep41487-fig-0006){ref-type="fig"}A), *Il‐6* (Fig. [6](#hep41487-fig-0006){ref-type="fig"}B), *Il‐1β* (Fig. [6](#hep41487-fig-0006){ref-type="fig"}C) and *Mcp1* (Fig. [6](#hep41487-fig-0006){ref-type="fig"}D), as well as fibrogenic genes including *Tgfβ* (Fig. [6](#hep41487-fig-0006){ref-type="fig"}E), *α‐Sma* (Fig. [6](#hep41487-fig-0006){ref-type="fig"}F), *Col1a1* (Fig. [6](#hep41487-fig-0006){ref-type="fig"}G), and *Col1a2* (Fig. [6](#hep41487-fig-0006){ref-type="fig"}H). Overexpression of human CES1 decreased or normalized alcohol‐induced increases in these inflammatory or fibrogenic gene expression (Fig. [6](#hep41487-fig-0006){ref-type="fig"}A‐H). In addition, overexpression of human CES1 also normalized alcohol‐induced increases in plasma levels of TNFα (Fig. [6](#hep41487-fig-0006){ref-type="fig"}I), IL‐6 (Fig. [6](#hep41487-fig-0006){ref-type="fig"}J), and IL‐1β (Fig. [6](#hep41487-fig-0006){ref-type="fig"}K). Thus, human CES1 can prevent alcohol‐induced inflammatory response.

![Human CES1 prevents alcohol‐induced increases in pro‐inflammatory and fibrogenic genes. C57BL/6 mice were fed a control diet or alcohol as described in Fig. [4](#hep41487-fig-0004){ref-type="fig"} (n = 8 per group). Hepatic mRNA levels (A‐H) and plasma levels of TNFα (I), IL‐6 (J), and IL‐1β (K) were determined. *\*P* \< 0.05*, \*\*P* \< 0.01.](HEP4-4-527-g006){#hep41487-fig-0006}

Human CES1 Prevents Alcohol‐Induced Apoptosis {#hep41487-sec-0021}
---------------------------------------------

Alcohol‐induced apoptosis plays an important role in the development of AFLD. Alcohol significantly induced hepatic apoptosis, which was blunted by human CES1 overexpression (Fig. [7](#hep41487-fig-0007){ref-type="fig"}A,B). In addition, human CES1 also attenuated alcohol‐induced increases in hepatic MDA (Fig. [7](#hep41487-fig-0007){ref-type="fig"}C) and ROS (Fig. [7](#hep41487-fig-0007){ref-type="fig"}D) levels. Consistent with these observations, alcohol induced hepatic phosphorylated Smad2/3 and cleaved CASP3 levels, which were normalized or attenuated by overexpression of human CES1 (Fig. [7](#hep41487-fig-0007){ref-type="fig"}E‐G). Thus, hepatocyte‐specific expression of human CES1 prevents alcohol‐induced apoptosis likely by inhibiting ROS production, lipid peroxidation, and the TGFβ‐Smad2/3 pathway.

![Human CES1 reduces alcohol‐induced apoptosis and ROS formation. C57BL/6 mice were fed a control diet or alcohol as described in Fig. [4](#hep41487-fig-0004){ref-type="fig"} (n = 8 per group). (A) Representative images of TUNEL staining. (B) Hepatic apoptotic cells (percentage). (C) Hepatic MDA levels. (D) Hepatic 2\',7\'‐dichlorodihydrofluorescein levels. Hepatic proteins were detected by western blot assays (E), and hepatic phosphorylated versus total Smad2/3 (P/T‐Smad2/3) levels (F) and CASP3 levels (G) were determined. *\*P* \< 0.05*, \*\*P* \< 0.01. Abbreviation: DCF, 2\',7\'‐dichlorodihydrofluorescein.](HEP4-4-527-g007){#hep41487-fig-0007}

Discussion {#hep41487-sec-0022}
==========

FLD is one of the most common chronic liver diseases worldwide. So far, the pathogenic mechanisms remain to be determined. In patients with alcoholic liver disease, hepatic CES1 expression is reduced by 75%.[9](#hep41487-bib-0009){ref-type="ref"} However, the role of human CES1 in FLD remains unknown. Because mice have eight *Ces1* genes (*Ces1a‐Ces1h*) that have shown inconsistent functions, it is unlikely to infer what functions human CES1 may have based on mouse studies in which specific mouse *Ces1* gene is overexpressed or depleted. Therefore, it is imperative to investigate human CES1 using an appropriate approach. In this study, we overexpressed human CES1 specifically in mouse hepatocytes *in vivo*. Our data show that hepatocyte‐specific expression of human CES1 protects against Western diet or alcohol‐induced steatohepatitis, thus suggesting a role of human CES1 in the pathogenesis of FLD.

Previous studies have shown that human CES1 has CEH activity.[19](#hep41487-bib-0019){ref-type="ref"} When human CES1 hydrolyzes, cholesterol esters release FC, which may be oxidized to serve as a ligand for liver X receptors (LXRs). Activation of LXRs is known to induce the expression of CYP7A1,[30](#hep41487-bib-0030){ref-type="ref"} ABCG5, and ABCG8.[31](#hep41487-bib-0031){ref-type="ref"} When CYP7A1 is induced, more FC is converted to bile acids, leading to a reduction in hepatic FC levels. The reduced hepatic FC levels can induce SREBP2 expression and processing, leading to an increase in LDLR expression and uptake of LDL by hepatocytes. As a result, overexpression of human CES1 in the liver reduces plasma LDL‐C levels. In addition, human CES1 also induces hepatic ApoC‐II and LPL expression, which may account for the reduced plasma TG levels. Bile acids are endogenous ligands for farnesoid X receptor (FXR). Activation of the FXR is known to induce ApoC‐II,[32](#hep41487-bib-0032){ref-type="ref"} a co‐activator of LPL. Because human CES1 induces CYP7A1 expression and bile acid synthesis, CES1 induces ApoC‐II expression likely by activation of FXR.

In addition to the CEH activity shown by the Ghosh et al.,[19](#hep41487-bib-0019){ref-type="ref"} we demonstrate that human CES1 has TGH activity. By hydrolyzing TG to release FFAs, human CES1 promotes FAO to lower hepatic TG and FFA levels. Interestingly, human CES1 does not regulate genes involved in *de novo* lipogenesis or VLDL secretion. Although we cannot fully rule out the possibility that human CES1 may regulate *de novo* lipogenesis or VLDL secretion, our data suggest that human CES1 lowers hepatic TG levels likely by inducing lipolysis and subsequent FAO.

The progression of FLD from simple steatosis to steatohepatitis needs additional "hits," such as ROS, apoptosis, and/or inflammation. FFA or FC‐induced lipotoxicity contributes to lipid peroxidation, ROS production, apoptosis, and inflammation.[25](#hep41487-bib-0025){ref-type="ref"}, [26](#hep41487-bib-0026){ref-type="ref"}, [27](#hep41487-bib-0027){ref-type="ref"} In our current study, we demonstrate that human CES1 overexpression reduces hepatic FFA and FC levels, lipid peroxidation, ROS production, apoptosis and inflammation, which together help address how human CES1 overexpression attenuates steatohepatitis.

In summary, our present data have demonstrated an important role of human CES1 in the pathogenesis of FLD and hyperlipidemia. Importantly, we have also uncovered the underlying mechanisms, which likely involve both the CEH and TGH activities of CES1. Our data suggest that human CES1 may be a useful drug target for treatment of FLD and related hyperlipidemia.
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